Benitec Biopharma (BNTC) Common Equity (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Common Equity for 7 consecutive years, with -$219.4 million as the latest value for Q1 2025.
- Quarterly Common Equity fell 2007.57% to -$219.4 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$219.4 million through Mar 2025, down 2007.57% year-over-year, with the annual reading at $47.2 million for FY2024, 23290.1% up from the prior year.
- Common Equity hit -$219.4 million in Q1 2025 for Benitec Biopharma, down from -$993000.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $47.2 million in Q2 2024 to a low of -$219.4 million in Q1 2025.
- Historically, Common Equity has averaged -$1.7 million across 5 years, with a median of $10.9 million in 2021.
- Biggest five-year swings in Common Equity: skyrocketed 23290.1% in 2024 and later plummeted 2007.57% in 2025.
- Year by year, Common Equity stood at $10.8 million in 2021, then fell by 17.0% to $9.0 million in 2022, then skyrocketed by 72.0% to $15.5 million in 2023, then tumbled by 106.42% to -$993000.0 in 2024, then crashed by 21991.74% to -$219.4 million in 2025.
- Business Quant data shows Common Equity for BNTC at -$219.4 million in Q1 2025, -$993000.0 in Q3 2024, and $47.2 million in Q2 2024.